Giulio Marchesini
Giulio Marchesini
Professor of Medicine, University of Bologna
Verified email at
Cited by
Cited by
Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes
B Zinman, C Wanner, JM Lachin, D Fitchett, E Bluhmki, ...
New England Journal of Medicine 373 (22), 2117-2128, 2015
Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome
G Marchesini, E Bugianesi, G Forlani, F Cerrelli, M Lenzi, R Manini, ...
Hepatology 37 (4), 917-923, 2003
Nonalcoholic fatty liver disease: a feature of the metabolic syndrome
G Marchesini, M Brizi, G Bianchi, S Tomassetti, E Bugianesi, M Lenzi, ...
Diabetes 50 (8), 1844-1850, 2001
Empagliflozin and progression of kidney dsease in type 2 diabetes
C Wanner, SE Inzucchi, JM Lachin, D Fitchett, M von Eynatten, ...
New england journal of medicine 375 (4), 323-334, 2016
The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD
P Angulo, JM Hui, G Marchesini, E Bugianesi, J George, GC Farrell, ...
Hepatology 45 (4), 846-854, 2007
Association of nonalcoholic fatty liver disease with insulin resistance
G Marchesini, M Brizi, AM Morselli-Labate, G Bianchi, E Bugianesi, ...
The American journal of medicine 107 (5), 450-455, 1999
Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma
E Bugianesi, N Leone, E Vanni, G Marchesini, F Brunello, P Carucci, ...
Gastroenterology 123 (1), 134-140, 2002
Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study
G Bedogni, L Miglioli, F Masutti, C Tiribelli, G Marchesini, S Bellentani
Hepatology 42 (1), 44-52, 2005
A position statement on NAFLD/NASH based on the EASL 2009 special conference
V Ratziu, S Bellentani, H Cortez-Pinto, C Day, G Marchesini
Journal of hepatology 53 (2), 372-384, 2010
A randomized, controlled trial of 3.0 mg of liraglutide in weight management
X Pi‑Sunyer, A Astrup, K Fujioka, F Greenway, A Halpern, M Krempf, ...
New England Journal of Medicine 373 (1), 11-22, 2015
Metformin in non-alcoholic steatohepatitis
G Marchesini, G Bianchi, S Tomassetti, M Zoli, N Melchionda
The Lancet 358 (9285), 893-894, 2001
Insulin resistance: a metabolic pathway to chronic liver disease
E Bugianesi, AJ McCullough, G Marchesini
Hepatology 42 (5), 987-1000, 2005
Clinical features and natural history of nonalcoholic steatosis syndromes
Y Falck-Ytter, ZM Younossi, G Marchesini, AJ McCullough
Seminars in liver disease 21 (1), 15-22, 2001
EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease
G Marchesini, CP Day, JF Dufour, A Canbay, V Nobili, V Ratziu, H Tilg, ...
Journal of Hepatology 64 (6), 1388-1402, 2016
A Randomized Controlled Trial of Metformin versus Vitamin E or Prescriptive Diet in Nonalcoholic Fatty Liver Disease
E Bugianesi, E Gentilcore, R Manini, S Natale, E Vanni, N Villanova, ...
The American journal of gastroenterology 100 (5), 1082, 2005
EASL-EASD-EASO Clinical Practice Guidelines for the management of nonalcoholic fatty liver disease
EA the Study of the Liver (EASL), EA the Study of Diabetes (EASD), ...
Journal of Hepatology 64 (6), 1388-1402, 2016
EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
European Association for The Study of The Liver, ...
Obesity facts 9 (2), 65-90, 2016
Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease
N Villanova, S Moscatiello, S Ramilli, E Bugianesi, D Magalotti, E Vanni, ...
Hepatology 42 (2), 473-480, 2005
Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes
AL Fracanzani, L Valenti, E Bugianesi, M Andreoletti, A Colli, E Vanni, ...
Hepatology 48 (3), 792-798, 2008
A survey of adverse events in 11241 patients with chronic viral hepatitis treated with alfa interferon
G Fattovich, G Giustina, S Favarato, A Ruol, ...
Journal of Hepatology 24 (1), 38-47, 1996
The system can't perform the operation now. Try again later.
Articles 1–20